Global Preimplantation Genetic Screening (PGS) Technology Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The global Preimplantation Genetic Screening (PGS) technology market is segmented into various product types including equipment, reagents and consumables, and software. Equipment, such as next-generation sequencing (NGS) machines and polymerase chain reaction (PCR) devices, dominate the market due to their critical role in genetic screening processes. Reagents and consumables, which include testing kits and reagents essential for sample processing, also hold a significant share, driven by their frequent usage and necessity in the screening procedures. Software solutions are increasingly gaining traction, offering advanced data analysis and interpretation capabilities, thus enhancing the efficiency and accuracy of genetic screening.

PGS technology is segmented based on the technology used, including next-generation sequencing (NGS), microarray, and polymerase chain reaction (PCR). NGS holds the largest share in the market due to its high accuracy, comprehensive analysis, and ability to detect a wide range of genetic abnormalities. Microarray technology is also widely used for its capability to analyze multiple genes simultaneously and its cost-effectiveness compared to NGS. PCR remains a significant technology in PGS due to its simplicity and reliability in detecting specific genetic markers.

The market is segmented by application into fertility clinics, hospitals, and research laboratories. Fertility clinics are the largest segment, driven by the increasing demand for advanced genetic screening to enhance the success rates of in vitro fertilization (IVF) procedures. Hospitals are also major users of PGS technology, particularly for patients undergoing genetic screening as part of their diagnostic or treatment processes. Research laboratories contribute to market growth through their role in advancing PGS technologies and conducting innovative studies that further drive the adoption of these technologies.

End-users of PGS technology include diagnostic laboratories, academic and research institutions, and biotechnology companies. Diagnostic laboratories are key end-users, leveraging PGS technology for its ability to provide accurate genetic information that aids in clinical decision-making. Academic and research institutions use PGS for research purposes, including developing new technologies and expanding knowledge on genetic disorders. Biotechnology companies are involved in the commercialization of PGS technologies and their integration into various clinical and research applications.

The market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America holds the largest market share, driven by advanced healthcare infrastructure, high adoption rates of innovative technologies, and significant investments in research and development. Europe follows closely, with a strong presence of key players and supportive government policies promoting genetic research and screening. The Asia-Pacific region is expected to experience significant growth due to increasing awareness, improving healthcare infrastructure, and rising demand for fertility treatments. Latin America and the Middle East & Africa are emerging markets, with growth fueled by expanding healthcare access and increasing investments in genetic screening technologies.

Global Preimplantation Genetic Screening (PGS) Technology Segment Analysis

In this report, the Global Preimplantation Genetic Screening (PGS) Technology Market has been segmented by Procedure Type, Technology, Test Type, Application, End User and Geography.

Global Preimplantation Genetic Screening (PGS) Technology Market, Segmentation by Geography

In this report, the Global Preimplantation Genetic Screening (PGS) Technology Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Preimplantation Genetic Screening (PGS) Technology Market Share (%), by Geographical Region, 2024

North America stands out as a prominent market for PGS technology, owing to its advanced healthcare infrastructure, high prevalence of genetic disorders, and substantial investments in research and development. The United States, in particular, is a major player due to its well-established fertility clinics and strong focus on reproductive health innovations. The North American market is expected to continue its growth trajectory, supported by ongoing technological advancements and increasing adoption of PGS in assisted reproductive technologies.

Europe also presents a significant market for PGS technology, with many countries in the region adopting advanced genetic screening practices. The European market benefits from a robust healthcare system, supportive regulatory frameworks, and increasing public awareness about genetic testing. Countries such as Germany, the United Kingdom, and France are leading the adoption of PGS technology, driven by their strong emphasis on reproductive health and genetic research.

Asia Pacific is witnessing rapid growth in the PGS technology market, driven by rising disposable incomes, increasing fertility rates, and growing awareness of genetic disorders. Countries like China and India are experiencing a surge in demand for advanced reproductive technologies, including PGS. The region's expanding healthcare infrastructure and improving access to genetic screening services are expected to fuel continued market growth.

The Middle East and Africa represent emerging markets for PGS technology, with growing interest in advanced reproductive technologies. The market in this region is characterized by increasing investments in healthcare infrastructure, rising awareness of genetic disorders, and a growing number of fertility clinics. However, the market's growth may be tempered by variations in healthcare accessibility and regulatory challenges across different countries.

Latin America is also witnessing a gradual increase in the adoption of PGS technology. The region's market growth is driven by expanding healthcare services, increasing awareness of genetic testing, and a growing number of fertility treatments. Countries like Brazil and Mexico are leading the way, with improvements in healthcare infrastructure and increasing access to advanced reproductive technologies contributing to market growth.

Overall, the global PGS technology market is poised for significant growth from 2020 to 2030, with varying trends and developments across different regions. Advancements in technology, increasing demand for personalized healthcare, and growing awareness of genetic disorders are key factors driving the market's expansion.

This report provides an in depth analysis of various factors that impact the dynamics of Global Preimplantation Genetic Screening (PGS) Technology Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing Awareness of Genetic Disorders
• Rising IVF Procedures
• Government Support and Funding

• Accuracy of Screening Methods -Preimplantation Genetic Screening (PGS) technology has revolutionized the field of reproductive medicine by allowing for the early detection of genetic abnormalities in embryos before implantation. This advancement has been instrumental in improving the success rates of in vitro fertilization (IVF) and reducing the risk of genetic disorders in newborns.

  The accuracy of PGS technology is largely determined by the method used for genetic screening. The two primary techniques are Comparative Genomic Hybridization (CGH) and Next-Generation Sequencing (NGS). Both methods have their strengths and limitations.

  CGH involves comparing the DNA of an embryo with a reference genome to identify chromosomal abnormalities. This method is effective in detecting aneuploidies—abnormal numbers of chromosomes—but has limitations in detecting smaller genetic variations or mutations. While CGH offers high sensitivity and specificity for chromosomal abnormalities, its accuracy can be affected by factors such as the quality of the DNA sample and the complexity of the genetic variations.

  NGS represents a more advanced approach that provides a comprehensive analysis of the entire genome. It offers superior resolution compared to CGH, enabling the detection of smaller genetic abnormalities and offering a more detailed picture of the embryo's genetic makeup. NGS has shown higher accuracy in identifying chromosomal abnormalities and genetic mutations, though it requires more advanced technology and data analysis capabilities. The increased detail provided by NGS can also lead to more nuanced interpretations of the genetic information.

  Overall, the accuracy of PGS technology has significantly improved over the years, thanks to advancements in genetic screening methods. However, the choice of screening method and the interpretation of results can impact the overall effectiveness of PGS. As technology continues to evolve, future developments may further enhance the precision and reliability of PGS, ultimately improving outcomes for individuals undergoing fertility treatments.

Restraints:

• High Costs of PGS Procedures
• Ethical and Moral Concerns
• Regulatory and Legal Challenges

• Potential for False Positives/Negatives -Preimplantation Genetic Screening (PGS) is a pivotal technology in assisted reproductive technology (ART), offering prospective parents a way to screen embryos for genetic abnormalities before implantation. Despite its significant advantages, PGS technology is not without limitations, particularly regarding the potential for false positives and false negatives.

  False positives in PGS occur when the technology incorrectly indicates that an embryo has a genetic abnormality when, in fact, it does not. This can lead to the unnecessary exclusion of otherwise healthy embryos from the implantation process. Several factors contribute to false positives, including the complexity of genetic data interpretation and the limitations of the technology itself. For instance, the accuracy of PGS can be affected by the number of cells sampled from the embryo. If the sample contains a higher proportion of cells with genetic abnormalities due to mosaicism (where not all cells are genetically identical), the PGS results may inaccurately suggest an abnormality. Furthermore, technical issues such as errors in DNA amplification or sequencing can also contribute to false positive results.

  False negatives occur when PGS fails to detect an actual genetic abnormality in an embryo, potentially leading to the implantation of embryos with undiagnosed issues. Factors that contribute to false negatives include the sensitivity of the technology and the possibility of missing subtle genetic mutations or anomalies. Like false positives, false negatives can also result from mosaicism, where the abnormal cells may not be present in the sampled cells or are present in very low frequencies, making them difficult to detect. Additionally, limitations in the resolution of the genetic testing methods used in PGS can sometimes fail to identify certain types of genetic abnormalities.

  To mitigate the risk of false positives and false negatives, ongoing advancements in PGS technology aim to improve accuracy and reliability. This includes refining sampling techniques, enhancing genetic sequencing methods, and integrating more sophisticated data analysis algorithms. Additionally, patient education and counseling are crucial in managing expectations and making informed decisions based on PGS results. By addressing these challenges, the global PGS technology market can enhance its effectiveness and support better outcomes in reproductive health.

Opportunities:

• Expansion into Emerging Markets
• Partnerships with Fertility Clinics
• Research and Development Investment

• Rising Acceptance of Genomic Medicine -The global Preimplantation Genetic Screening (PGS) technology market is experiencing notable growth due to the increasing acceptance of genomic medicine. As advancements in genetic testing and genomic analysis become more sophisticated, PGS technology has emerged as a vital tool in reproductive medicine. PGS involves the genetic screening of embryos prior to implantation during in vitro fertilization (IVF) procedures. This technology allows for the identification of genetic abnormalities and ensures the transfer of genetically healthy embryos, thereby improving the chances of successful pregnancy and reducing the risk of genetic disorders.

  The rising acceptance of genomic medicine is a key driver behind the expansion of the PGS market. As patients and healthcare providers become more aware of the benefits of genomic insights, there is a growing demand for advanced reproductive technologies that incorporate genetic screening. Genomic medicine, with its focus on personalized healthcare and precision treatments, aligns well with the objectives of PGS, which aims to enhance reproductive outcomes by minimizing the risk of genetic conditions.

  The integration of genomic medicine into routine clinical practice is fostering a more proactive approach to reproductive health. The ability to screen embryos for genetic anomalies before implantation aligns with the broader trend of utilizing genomic data to tailor medical interventions to individual needs. This shift towards personalized medicine is expected to further propel the growth of the PGS technology market, as more couples and individuals seek to leverage these advancements for better reproductive outcomes.

  In summary, the global PGS technology market is poised for significant growth, driven by the increasing acceptance and integration of genomic medicine. As advancements in genetic screening continue to evolve, PGS technology is becoming an essential component of reproductive medicine, offering enhanced precision and improved outcomes for individuals undergoing fertility treatments.

Key players in Global Preimplantation Genetic Screening (PGS) Technology Market include;

• Illumina, Inc
• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc
• PerkinElmer Inc
• Coopersurgical, Inc
• Abbott Laboratories
• Natera, Inc
• Takara Bio Inc
• Oxford Gene Technology
• INVICTA Sp. z o.o
• Genea Limited
• Progenesis
• Igenomix
• Reproductive Health and Wellness Center
• Elucigene Diagnostics
• Arrayit Corporation
• Macrogen, Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis